Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance Therapeutics to Release Fourth Quarter and Full Year 2015 Financial Results Wednesday, March 2, 2016

GlobeNewswire February 17, 2016

Revance Specifies 2016 Clinical Program Milestones

GlobeNewswire January 7, 2016

Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis

GlobeNewswire December 23, 2015

Revance Appoints Abhay Joshi, PhD, as Chief Operating Officer

GlobeNewswire December 14, 2015

Revance Therapeutics to Present in the 27th Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 19, 2015

Revance Therapeutics Releases Third Quarter 2015 Results

GlobeNewswire November 9, 2015

Revance Therapeutics Announces Closing of Public Offering of Common Stock

GlobeNewswire November 9, 2015

Revance Therapeutics to Present at Credit Suisse 24th Annual Healthcare Conference

GlobeNewswire November 4, 2015

Revance Therapeutics to Release Third Quarter 2015 Financial Results Monday, November 9, 2015

GlobeNewswire November 4, 2015

Revance Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire November 4, 2015

Revance Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire November 2, 2015

Revance Reports Positive 6-Month Duration in BELMONT Study

GlobeNewswire October 29, 2015

Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia

GlobeNewswire September 29, 2015

Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines

GlobeNewswire September 28, 2015

Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis

GlobeNewswire September 9, 2015

IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims Against Revance Therapeutics, Inc. on Behalf of Investors

Business Wire September 3, 2015

INVESTOR ALERT: Investigation of Revance Therapeutics, Inc. Announced by The Law Offices of Howard G. Smith

Business Wire September 3, 2015

Revance Therapeutics Releases Second Quarter 2015 Results

GlobeNewswire August 6, 2015

Revance Therapeutics to Release Second Quarter 2015 Financial Results Thursday, August 6, 2015

GlobeNewswire July 23, 2015

Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.

GlobeNewswire July 2, 2015